Atara announces FDA Type A meeting to discuss tabelecleucel BLA resubmission

Atara Biotherapeutics, Inc.

Type A meeting with FDA scheduled to discuss Complete Response Letter from Jan 9, 2026.
Partner Pierre Fabre to lead the meeting with Atara's support.
Goal: collaboratively address CRL points for resubmission using additional efficacy data.
Regulatory update expected in Q2 2026.

item 8.01 item 9.01

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-103127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.